Physician profile
Haritha Bellam
NPI 1770883191
$4,796.37
in general payments reported to CMS, 2019-2025
16 companies · $462 in 2025
The $462 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $689 · 2020: $399 · 2021: $809 · 2022: $840 · 2023: $829 · 2024: $768 · 2025: $462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,059.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,059.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,827.03 | 2019-2025 | Rinvoq, Skyrizi |
| Glaxosmithkline, LLC. | $882.69 | 2019-2025 | Benlysta |
| Genentech USA, INC. | $457.63 | 2019-2025 | Actemra, Rituxan, Gazyva |
| Horizon Therapeutics Plc | $374.89 | 2019-2023 | Krystexxa |
| Pfizer INC. | $348.03 | 2019-2025 | |
| Amgen INC. | $236.35 | 2022-2025 | Krystexxa, Evenity, Prolia |
| E.R. Squibb & Sons, L.L.C. | $147.68 | 2019-2024 | Orencia |
| Novartis Pharmaceuticals Corporation | $140.56 | 2020-2024 | |
| Octapharma USA, INC. | $134.75 | 2021-2022 | |
| Janssen Biotech, INC. | $118.59 | 2019-2024 | Tremfya |
| Aurinia Pharma U.S., INC. | $37.33 | 2021-2025 | Lupkynis |
| Radius Health, INC. | $35.05 | 2023 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.01 | 2022 | |
| Ucb, INC. | $14.84 | 2024 | Cimzia |
| Genzyme Corporation | $12.62 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Therapeutics, INC. | $12.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haritha Bellam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.